Anna Jonášová - Concepedia

Author

Anna Jonášová

Also Known As

A Jonasova, A Jonásová, A Jonášová, A. Jonasova, A. Jonáŝová, A. Jonášová, A.T. Jonasova, ANNA JONASOVA, Anna Jonasova, Anna JonÁšovÁ

235

Publications

Citations

H-Index

Concepts

All Affiliations

Charles University General University Hospital in Prague Institute of Haematology and Blood Transfusion Université Paris Cité University of Florence

About

Anna Jonášová is an author at Charles University specializing in medicine, hematology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	16	800
2	Cell Biology	7	7	236
3	Health Sciences	5	5	332
4	Natural Sciences	1	1	42
5	Emergency Medicine	1	1	154

Anna Jonášová

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents Valeria Santini, António Almeida, Aristoteles Giagounidis, Journal of Clinical Oncology	2016	213
Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow Anna Jonášová, R Neuwírtová, Jaroslav Čermák, British Journal of Haematology	1998	212
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, The Lancet Hematological MalignancyThrombosisInterim AnalysisBone Marrow FailurePhase 3	2023	154
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial Uwe Platzbecker, Valeria Santini, Pierre Fenaux, The Lancet Hematological MalignancyThrombosisErythropoiesis-stimulating AgentsBone Marrow FailureMalignant Blood Disorder	2023	118
Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation Vít Pospíšil, Karin Vargová, Juraj Kokavec, The EMBO Journal Epigenetic SilencingPu.1-directed Macrophage DifferentiationGene ExpressionOncogenic Mir-17-92 ClusterMicrorna Detection	2011	94
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML Jingrui Jiang, J. Guillermo Paez, Jeffrey C. Lee, Blood	2004	83
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes Guillermo Garcia‐Manero, Valeria Santini, António Almeida, Journal of Clinical Oncology	2021	75
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes Fabio Efficace, Gianluca Gaïdano, Massimo Breccia, British Journal of Haematology Quality Of LifeFatigue SeverityLife AssessmentDiagnosisAplastic Anemia	2014	74
<i>TP53</i> mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes Monika Beličková, Jitka Veselá, Anna Jonášová, Oncotarget Mixed-phenotype Acute LeukemiaGeneticsGenetic EpidemiologyPathologyPotential Predictor	2016	55
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial Matteo Della Porta, Guillermo Garcia‐Manero, Valeria Santini, The Lancet Haematology Hematological MalignancyThrombosisTranslational MedicineBone Marrow FailureBlood Transfusion	2024	44

Page 1